hepatitis
Novartis drops two drug candidates, takes $600 million hit
October 6, 2010Research and Development Human Genome Sciences, Novartis, candidiasis, hepatitis
Novartis will incur a charge of nearly $600 million after it halted development of investigational drugs for hepatitis C and …
BMS to acquire ZymoGenetics
September 8, 2010Research and Development, Sales and Marketing BMS, hepatitis
Bristol-Myers Squibb is to acquire biopharma company ZymoGenetics for $885 million to add to its ‘string of pearls’of small biotech …
New Pegasys licence gives patients ‘second chance for a cure’
December 4, 2008Sales and Marketing Roche, hepatitis
Hepatitis C patients who don't at first respond to treatment with Pegasys will now be able to receive the drug …
Call for universal Hepatitis B vaccination
August 22, 2008Sales and Marketing hepatitis
The pharma industry has joined up with patient groups to petition for universal Hepatitis B immunisation for all children in …
Latest content
Jennings becomes President of Beckman Coulter Diagnostics
October 19, 2026
Boyds expands Regulatory Affairs team to support growing demand
October 16, 2026
Sterling doubles ADC manufacturing capacity at Welsh facility
October 16, 2026
Femtosecond laser cuts lung tumour margin assessment time
October 15, 2026
